China Facial Injectable Market Size & Outlook, 2025-2030

The facial injectable market in China is expected to reach a projected revenue of US$ 4,162.2 million by 2030. A compound annual growth rate of 20.8% is expected of China facial injectable market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,347.1
Forecast, 2030 (US$M)
$4,162.2
CAGR, 2025 - 2030
20.8%
Report Coverage
China

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China facial injectable market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China facial injectable market highlights

  • The China facial injectable market generated a revenue of USD 1,347.1 million in 2024 and is expected to reach USD 4,162.2 million by 2030.
  • The China market is expected to grow at a CAGR of 20.8% from 2025 to 2030.
  • In terms of segment, botulinum toxin type a was the largest revenue generating product in 2024.
  • HA is the most lucrative product segment registering the fastest growth during the forecast period.


Facial injectable market data book summary

Market revenue in 2024USD 1,347.1 million
Market revenue in 2030USD 4,162.2 million
Growth rate20.8% (CAGR from 2025 to 2030)
Largest segmentBotulinum toxin type a
Fastest growing segmentHA
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCollagen, Botulinum Toxin Type A, HA, CaHA, PLLA


Other key industry trends

  • In terms of revenue, China accounted for 10.7% of the global facial injectable market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China facial injectable market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,162.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Facial Injectable Market Companies

Name Profile # Employees HQ Website
Galderma View profile 10001+ Lausanne, Vaud, Switzerland, Europe http://www.galderma.com
Medytox View profile 501-1000 Seoul, Seoul-t'ukpyolsi, South Korea, Asia http://www.medytox.com/page/company_en?site_id=en
Sinclair Pharma plc View profile 501-1000 London, England, United Kingdom, Europe http://www.sinclairpharma.com/
Merz Pharma View profile 5001-10000 Deutsch, Sachsen, Germany, Europe http://www.merz.com
Revance Therapeutics Inc View profile 597 1222 Demonbreun Street, Suite 2000, Nashville, TN, United States, 37203 https://www.revance.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com

China facial injectable market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to facial injectable market will help companies and investors design strategic landscapes.


Botulinum toxin type a was the largest segment with a revenue share of 89.66% in 2024. Horizon Databook has segmented the China facial injectable market based on collagen, botulinum toxin type a, ha, caha, plla covering the revenue growth of each sub-segment from 2018 to 2030.


China's Facial Injectable Market is witnessing significant growth, driven by expanding product availability, increasing aesthetic awareness, and growing consumer demand for non-invasive treatments. In May 2024, Galderma launched Restylane VOLYME in China, addressing mid-face aging concerns with its Shape Up Holistic Individualized Treatment (HIT) approach, reflecting a commitment to personalized aesthetic solutions.

Additionally, in September 2024, Allergan Aesthetics introduced BOTOX Cosmetic for the treatment of masseter muscle prominence (MMP), marking it as the first neurotoxin approved in China for this indication. With China’s medical aesthetics market outpacing global growth trends and relatively low market penetration, there remains vast potential for expansion.

As global leaders continue investing in advanced injectables and regulatory approvals increase, China's Facial Injectable Market is set for robust growth, fueled by a rising middle-class population, higher disposable incomes, and a growing emphasis on facial aesthetics.

Reasons to subscribe to China facial injectable market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China facial injectable market databook

  • Our clientele includes a mix of facial injectable market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China facial injectable market , including forecasts for subscribers. This country databook contains high-level insights into China facial injectable market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China Product - Facial Injectable Market size, 2024 - 2030 (US$M)

China Facial Injectable Market Outlook Share, 2024 & 2030 (US$M)

China Product - Facial Injectable Market size, 2024 - 2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online